Search results
-
ESMO 2024 – Torl challenges BioNTech in Claudin6
… of BNT211 was deemed to be toxic by the discussant at ESMO 2023 , Centre Léon Bérard’s Dr Philippe Cassier. …
- 09/16/2024 - 15:51 -
ESMO 2024 – Astra’s B7-H4 effort underwhelms
… inhibitor 6 Ph1 China study in solid tumours ESMO 2023: 29% ORR in 28 TNBC pts XMT-1660 Mersana …
- 09/15/2024 - 08:35 -
ESMO 2024 preview – Astellas’s KRAS degrader disappoints
… KRAS G12D inhibitor When presented ESMO 2024 ESMO 2023 Study Ph1 global study Ph1 …
- 09/12/2024 - 15:49 -
Amgen packs up in Claudin6
… Car-T Ph1 in solid tumours (NCT04503278) Data at ESMO 2023; ph2 in testicular germ cell tumours to start 2024 …
- 07/12/2024 - 12:32 -
IO Biotech looks for an interim injection
… & UBC + Keytruda (uncontrolled) Preliminary data at ESMO 2023; more data expected autumn 2024 PN-E40 …
- 06/27/2024 - 20:11 -
ASCO 2024 – full Evoke-01 result adds to Gilead’s Trodelvy problems
… and a secondary endpoint in Evoke-01. Source: ESMO 2023 & ASCO 2024. Conferences …
- 06/01/2024 - 22:08 -
EHA 2024 preview – Novartis doubles up
… Anti-CD123 NK cell engager S146 Had data at ESMO 2023 Roche Englumafusp alfa …
- 05/20/2024 - 18:11 -
J&J speeds into new bladder cancer trial
… pts with FGFR alterations Ph1 data at ESMO 2023: 87% CR rate in 15 pts in cohort 3 (BCG-naive) … BCG-experienced pts with FGFR mutations Data at ESMO 2023: 72% reduction in risk of recurrence/death in 73 … Ph2 Sunrise-1 in high-risk BCG-unresponsive pts, data at ESMO 2023: 77% CR rate in 30 pts Source: …
- 04/23/2024 - 13:00 -
BioNTech has some cancer convincing to do
… Car-T N/A Ph1/2 in solid tumours Data at ESMO 2023 showed promising efficacy, but with tox …
- 03/21/2024 - 13:20 -
AACR 2024 preview – clinical highlights and lowlights
… inhibitor 1L glioblastoma CT044 Had data at ESMO 2023 Cadonilimab Akeso Anti-PD-1 x CTLA-4 …
- 03/07/2024 - 15:52
